U.S. Markets closed

Ocera Therapeutics, Roche enter technology transfer and license agreement

Ocera Therapeutics (OCRX) announced that it has entered into a Technology Transfer and License Agreement with the Roche Group (RHHBY), including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry discovery platform. Under the terms of the agreement, Ocera will transfer ownership of equipment and materials related to the use of the MATCH technology, and grant a license to Genentech and Roche under Ocera's related intellectual property rights. The Roche Group will make a one-time payment to Ocera of $4M.